Literature DB >> 36104395

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.

Arsene Mekinian1, Lin Pierre Zhao2, Sylvie Chevret3, Kristell Desseaux3, Laurent Pascal4, Thibaut Comont5, Alexandre Maria6, Pierre Peterlin7, Louis Terriou8, Maud D'Aveni Piney9, Marie-Pierre Gourin10, Norbert Vey11, Odile Beyne Rauzy5, Vincent Grobost12, Holy Bezanahary13, Sophie Dimicoli-Salazar14, Anne Banos15, Stefan Wickenhauser16, Benoit De Renzis17, Eric Durot18, Shanti Natarajan-Amé19, Laurent Voillat10, Fatiha Chermat2, Karine Lemaire2, Vincent Jachiet20, Chantal Himberlin18, Sylvain Thépot21, Jose Miguel Torregrosa Diaz22, Laurent Frenzel23, Emmanuel Gyan24, Guillaume Denis25, Pierre Hirsch26, Olivier Kosmider27, Lionel Ades2, Olivier Fain20, Pierre Fenaux2.   

Abstract

Entities:  

Year:  2022        PMID: 36104395     DOI: 10.1038/s41375-022-01698-8

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  1 in total

Review 1.  VEXAS syndrome.

Authors:  Peter C Grayson; Bhavisha A Patel; Neal S Young
Journal:  Blood       Date:  2021-07-01       Impact factor: 25.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.